Since accumulation of Aβ and tau begins more than a decade before the manifestation of clinical symptoms of cognitive impairment, an early therapeutic intervention should produce more evident beneficial effects or even halt the progression to dementia. This evidence concerns the gene MAPT and Cognitive impairment.